Phase I trial of fenretinide delivered orally in a novel organized lipid complex in patients with relapsed/refractory neuroblastoma: A report from the new approaches to neuroblastoma therapy (NANT) consortium

Pediatric Blood and Cancer

Volumn 60, Issue 11, 2013, Pages 1801-1808

  Maurer, Barry J ^a   Kang, Min H ^a   Villablanca, Judith G ^b   Janeba, Jitka ^b   Groshen, Susan ^b   Matthay, Katherine K ^c   Sondel, Paul M ^d   Maris, John M ^e,f   Jackson, Hollie A ^b   Goodarzian, Fariba ^b   Shimada, Hiroyuki ^b   Czarnecki, Scarlett ^g   Hasenauer, Beth ^g   Reynolds, C Patrick ^a   Marachelian, Araz ^b  

^a TEXAS TECH UNIVERSITY HEALTH SCIENCES CENTER SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d UNIVERSITY OF WISCONSIN   (United States)

^e UNIVERSITY OF PENNSYLVANIA   (United States)

^f UNIVERSITY OF PENNSYLVANIA   (United States)

^g CHILDREN S HOSPITAL LOS ANGELES   (United States)

Author keywords

Fenretinide; LYM X SORB ; Neuroblastoma; Pediatric; Powder

Indexed keywords

ALKALINE PHOSPHATASE; AMINOTRANSFERASE; CYCLOPHOSPHAMIDE; FENRETINIDE; IODINE 131; ISOTRETINOIN; ZOLEDRONIC ACID;

ADOLESCENT; ADULT; ALKALINE PHOSPHATASE BLOOD LEVEL; AMINOTRANSFERASE BLOOD LEVEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; BONE DISEASE; CANCER PALLIATIVE THERAPY; CHILD; CLINICAL ARTICLE; DRUG BLOOD LEVEL; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; FEBRILE NEUTROPENIA; FEMALE; HUMAN; LIVER FUNCTION TEST; MALE; MAXIMUM TOLERATED DOSE; NEUROBLASTOMA; PHASE 1 CLINICAL TRIAL; POWDER; PRESCHOOL CHILD; PRIORITY JOURNAL; SCHOOL CHILD; SIDE EFFECT; TREATMENT RESPONSE; TUMOR GROWTH; TUMOR RECURRENCE;

FENRETINIDE; LYM-X-SORB™; NEUROBLASTOMA; PEDIATRIC; POWDER;

ADOLESCENT; ADULT; ANTINEOPLASTIC AGENTS; CHILD; CHILD, PRESCHOOL; FEMALE; FENRETINIDE; HUMANS; MALE; MAXIMUM TOLERATED DOSE; NEOPLASM RECURRENCE, LOCAL; NEUROBLASTOMA; YOUNG ADULT;

EID: 84883815321     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.24643     Document Type: Article

References (42)

1. Formelli F, Cleris L. Synthetic retinoid fenretinide is effective against a human ovarian carcinoma xenograft and potentiates cisplatin activity. Cancer Res 1993; 53:5374-5376.
2. Delia D, Aiello A, Lombardi L, et al. N-(4-hydroxyphenyl)retinamide induces apoptosis of malignant hemopoietic cell lines including those unresponsive to retinoic acid. Cancer Res 1993; 53:6036-6041.
3. Zou C-P, Kurie JM, Lotan D, et al. Higher potency of N-(4-hydroxyphenyl)retinamide than all-trans-retinoic acid in induction of apoptosis in non-small cell lung cancer cell lines. Clin Cancer Res 1998; 4:1345-1355.
4. Maurer BJ, Metelitsa LS, Seeger RC, et al. Increase of ceramide and induction of mixed apoptosis/necrosis by N-(4-hydroxyphenyl)-retinamide in neuroblastoma cell lines. J Natl Cancer Inst 1999; 91:1138-1146.
5. Oridate N, Suzuki S, Higuchi M, et al. Involvement of reactive oxygen species in N-(4-hydroxyphenyl)retinamide-induced apoptosis in cervical carcinoma cells. J Natl Cancer Inst 1997; 89:1191-1198.
6. Delia D, Aiello A, Meroni L, et al. Role of antioxidants and intracellular free radicals in retinamide-induced cell death. Carcinogenesis 1997; 18:943-948.
7. Sun SY, Li W, Yue P, et al. Mediation of N-(4-hydroxyphenyl)retinamide-induced apoptosis in human cancer cells by different mechanisms. Cancer Res 1999; 59:2493-2498.
8. Maurer BJ, Melton L, Billups C, et al. Synergistic cytotoxicity in solid tumor cell lines between N-(4-hydroxyphenyl)retinamide and modulators of ceramide metabolism. J Natl Cancer Inst 2000; 92:1897-1909.
9. O'Donnell PH, Guo W, Reynolds CP, et al. N-(4-hydroxyphenyl)retinamide increases ceramide and is cytotoxic to acute lymphoblastic leukemia cell lines, but not to non-malignant lymphocytes. Leukemia 2002; 16:902-910.
10. Batra S, Reynolds CP, Maurer BJ. Fenretinide cytotoxicity for Ewing's Sarcoma (ES) and primitive neuroectodermal tumor (PNET) cell lines is decreased by hypoxia and synergistically enhanced by ceramide modulators. Cancer Res 2004; 5415-5424.
11. Wang H, Maurer BJ, Liu Y-Y, et al. N-(4-hydroxyphenyl)retinamide increases dihydroceramides and synergizes with dimethylsphingosine to enhance cancer cell killing. Mol Cancer Ther 2008; 7:2967-2976.
12. Kraveka JM, Li L, Szulc ZM, et al. Involvement of the dihydroceramide desaturase in cell cycle progression in human neuroblastoma cells. J Biol Chem 2007; 282:16718-16728.
13. Rahmaniyan M, Curley RW, Jr., Obeid LM, et al. Identification of dihydroceramide desaturase as a direct in vitro target for fenretinide. J Biol Chem 2011; 286:24754-24764.
14. Ribatti D, Alessandri G, Baronio M, et al. Inhibition of neuroblastoma-induced angiogenesis by fenretinide. Int J Cancer 2001; 94:314-321.
15. Zhao Z, Matsuura T, Popoff K, et al. Effects of N-(4-hydroxyphenyl)-retinamide on the number and cytotoxicity of natural killer cells in vitamin-A-sufficient and -deficient rats. Nat Immun 1994; 13:280-288.
16. Gibbs IS, Kotwal PM. Pharmaceutical composition of N-(4-hydroxyphenyl) retinamide having increased bioavailability. U.S. Patent 4, 665, 098 1987.
17. Costa A, Formelli F, Chiesa F, et al. Prospects of chemoprevention of human cancers with the synthetic retinoid fenretinide. Cancer Res 1994; 54:2032-2037.
18. Cobleigh MA, Dowlatshahi K, Deutsch TA, et al. Phase I/II trial of tamoxifen with or without fenretinide, an analog of vitamin A, in women with metastatic breast cancer. J Clin Oncol 1993; 11:474-477.
19. Chiesa F, Tradati N, Marazza M, et al. Fenretinide (4-HPR) in chemoprevention of oral leukoplakia. J Cell Biochem Suppl 1993; 17F:255-261.
20. Formelli F, Clerici M, Campa T, et al. Five-year administration of fenretinide: Pharmacokinetics and effects on plasma retinol concentrations. J Clin Oncol 1993; 11:2036-2042.
21. Costa A, Malone W, Perloff M, et al. Tolerability of the synthetic retinoid fenretinide (HPR). Eur J Cancer Clin Oncol 1989; 25:805-808.
22. Camerini T, Mariani L, de Palo G, et al. Safety of the synthetic retinoid fenretinide: Long-term results from a controlled clinical trial for the prevention of contralateral breast cancer. J Clin Oncol 2001; 19:1664-1670.
23. Garaventa A, Luksch R, Piccolo MS, et al. Phase I trial and pharmacokinetics of fenretinide in children with neuroblastoma. Clin Cancer Res 2003; 9:2032-2039.
24. Villablanca JG, London WB, Naranjo A, et al. Phase II study of oral capsular 4-hydroxyphenylretinamide (4-HPR/fenretinide) in pediatric patients with refractory or recurrent neuroblastoma: A report from the Children's Oncology Group NSC # 374551; IND# 40294. Clin Cancer Res 2011; 17:6858-6866.
25. Villablanca JG, Krailo MD, Ames MM, et al. Phase I trial of oral fenretinide in children with high risk solid tumors: A report from the Children's Oncology Group (CCG 09709). J Clin Oncol 2006; 24:3423-3430.
26. Schneider BJ, Worden FP, Gadgeel SM, et al. Phase II trial of fenretinide (NSC 374551) in patients with recurrent small cell lung cancer. Invest New Drugs 2009; 27:571-578.
27. Maurer BJ, Kalous O, Yesair DW, et al. Improved oral delivery of N-(4-hydroxyphenyl)retinamide with a novel LYM-X-SORB organized lipid complex. Clin Cancer Res 2007; 13:3079-3086.
28. Brodeur GM, Pritchard J, Berthold F, et al. Revisions of the international criteria for neuroblastoma diagnosis, staging and response to treatment. Prog Clin Biol Res 1994; 385:363-369. 363-369.
29. Lin Y, Shih WJ. Statistical properties of the traditional algorithm-based designs for phase I cancer clinical trials. Biostatistics 2001; 2:203-215.
30. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000; 92:205-216.
31. 123I-MIBG whole body scan scoring method-application to the prediction of the response of metastases to induction chemotherapy in stage IV neuroblastoma. Eur J Cancer 1995; 31A:256-261.
32. 131-metaiodobenzylguanidine double infusion with autologous stem-cell rescue for neuroblastoma: A new approaches to neuroblastoma therapy phase I study. J Clin Oncol 2009; 27:1020-1025.
33. Vratilova J, Frgala T, Maurer BJ, et al. Liquid chromatography method for quantifying N-(4-hydroxyphenyl)retinamide and N-(4-methoxyphenyl)retinamide in tissues. J Chromatogr B Analyt Technol Biomed Life Sci 2004; 808:125-130.
34. Rayburg M, Towbin A, Yin H, et al. Langerhans cell histiocytosis in a patient with stage 4 neuroblastoma receiving oral fenretinide. Pediatr Blood Cancer 2009; 53:1111-1113.
35. Lee JS, Newman RA, Lippman SM, et al. Phase I evaluation of all-trans retinoic acid with and without ketoconazole in adults with solid tumors. J Clin Oncol 1995; 13:1501-1508.
36. Cooper JP, Hwang K, Singh H, et al. Fenretinide metabolism in humans and mice: Utilizing pharmacological modulation of its metabolic pathway to increase systemic exposure. Br J Pharmacol 2011; 163:1263-1275.
37. Kummar S, Gutierrez ME, Maurer BJ, et al. Phase I trial of fenretinide lym-x-sorb oral powder in adults with solid tumors and lymphomas. Anticancer Res 2011; 31:961-966.
38. DuBois SG, Kalika Y, Lukens JN, et al. Metastatic sites in stage IV and IVS neuroblastoma correlate with age, tumor biology, and survival. J Pediatr Hematol Oncol 1999; 21:181-189.
39. 131I-MIBG semi-quantitative scores in predicting survival in patients with stage 4 neuroblastoma: A report from the Children's Oncology Group. Pediatr Blood Cancer 2011; 56:1041-1045.
40. 123I-metaiodobenzylguanidine scintigraphy with overall response and event-free survival in stage IV neuroblastoma. J Clin Oncol 2003; 21:2486-2491.
41. Bagatell R, London WB, Wagner LM, et al. Phase II study of irinotecan and temozolomide in children with relapsed or refractory neuroblastoma: A Children's Oncology Group study. J Clin Oncol 2011; 29:208-213.
42. Shusterman S, London WB, Gillies SD, et al. Antitumor activity of hu14.18-IL2 in patients with relapsed/refractory neuroblastoma: A Children's Oncology Group (COG) phase II study. J Clin Oncol 2010; 28:4969-4975.